TCGA-KU-A6H7-06A-21R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.530
- DNA_REPAIR+0.360
- E2F_TARGETS+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- MYC_TARGETS_V1+0.270
- FATTY_ACID_METABOLISM+0.190
- ADIPOGENESIS+0.180
- ALLOGRAFT_REJECTION+0.150
- MYC_TARGETS_V2+0.130
- KRAS_SIGNALING_DN+0.100
Top 10 suppressed
- UV_RESPONSE_DN-0.480
- ANGIOGENESIS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- HEDGEHOG_SIGNALING-0.430
- PROTEIN_SECRETION-0.380
- TGF_BETA_SIGNALING-0.350
- MITOTIC_SPINDLE-0.330
- KRAS_SIGNALING_UP-0.320
- ANDROGEN_RESPONSE-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A6UY-01A-12R-A34R-07 | — | — | 0.924 |
| 2 | TCGA-UP-A6WW-01A-12R-A34R-07 | — | — | 0.867 |
| 3 | TCGA-P3-A6SW-01A-11R-A34R-07 | — | — | 0.861 |
| 4 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.857 |
| 5 | TCGA-P3-A5Q5-01A-11R-A28V-07 | — | — | 0.845 |
| 6 | TCGA-IQ-A61I-01A-11R-A30B-07 | — | — | 0.845 |
| 7 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.844 |
| 8 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.841 |
| 9 | TCGA-GV-A6ZA-01A-12R-A33J-07 | — | — | 0.830 |
| 10 | TCGA-TN-A7HI-01A-11R-A34R-07 | — | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.530 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |